Asterias Biotherapeutics Inc., of Fremont, Calif., and Biotime Inc., of Alameda, Calif., along with Biotime's wholly owned subsidiary ES Cell International Pte Ltd., have entered into a share transfer agreement through which Biotime will re-acquire from Asterias shares of capital stock of Biotime subsidiaries Cell Cure Neurosciences Ltd. and Orthocyte Corp.
Researchers at the University of Texas Southwestern Medical Center have developed a method for identifying cell lines that could be used as a chemical screen to simultaneously predict multiple pathway-level effects of drugs.
Cancer metastases do not spread randomly. Certain tumor types preferentially settle in certain organs, a phenomenon that has been explained by postulating specific interactions between metastatic seeds and the soil of the organ where those seeds settle.
Otsuka Pharmaceuticals Co. Ltd., of Tokyo, and H. Lundbeck, A/S, of Valby, Denmark, said the FDA expanded the label of Abilify Maintena (aripiprazole) for extended-release injectable suspension to include a new injection site, the deltoid muscle of the arm. Healthcare providers will now have the option for either a gluteal or deltoid injection site for administering Abilify Maintena to patients with schizophrenia.
The CONVERGE consortium has identified the first genetic risk loci for depression. Genetic risk factors for major depressive disorder have been surprisingly hard to pin down, with several major genomewide association studies coming up empty.
Georg-August-University Göttingen (UMG) and MRC Technology (MRCT), of London, signed an exclusive license to develop a therapy for neurodegenerative diseases based on antibody-targeting amyloid beta peptides.
Researchers from McGill University have shown that the immune system contribution to chronic pain differs in male and female mice. A large body of research suggests the hypersensitivity to normal stimuli, part of chronic pain, is due in part to immune cell signaling. Specifically, such signaling is from microglia to neurons.